{"slug":"brca","tag":"brca","variants":["brca"],"description":"No description yet","count":4,"kinds":{"person":1,"biomarker":3},"related":[{"slug":"biomarker","tag":"biomarker","shared":3},{"slug":"genome-wide","tag":"genome-wide","shared":1},{"slug":"pancreatic","tag":"pancreatic","shared":1},{"slug":"parp","tag":"parp","shared":1}],"records":[{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/","tldr":"Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers."},{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/","tldr":"A germline BRCA1 or BRCA2 variant is inherited and present in every cell, found by a blood test. It selects PARP inhibitors in breast, ovarian, pancreatic and prostate cancer and tells relatives they may carry it too."},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/","tldr":"Tumour BRCA testing finds BRCA1/2 mutations in the cancer itself, whether inherited or acquired; wider panels add other repair genes such as ATM and PALB2. Ovarian and prostate cancer labels accept the tumour result for PARP inhibitors."},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/","tldr":"HRD-positive means the tumour's genome carries the scars of failed double-strand break repair (or a BRCA mutation), measured as a genomic instability score. In ovarian cancer it selects niraparib, and olaparib with bevacizumab, as first-line maintenance."}]}